Clinical trial
Study of Glucarpidase (CPG2) for the Management of Patients With Delayed…
NCT00219791 · BTG International Inc., Other · Completed
Key facts
| NCT number | NCT00219791 |
|---|---|
| Title | Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance |
| Official title | Study of Recombinant Carboxypeptidase G2 (CPG2) for the Management of Patients With Delayed Methotrexate (MTX) Clearance or Intrathecal MTX Overdosage |
| Lead sponsor | BTG International Inc., Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | glucarpidase (50 Units/kg) |
| Start date | Jan 1, 2000 |
| Completion | Jun 1, 2003 |
| First posted | Sep 22, 2005 |
| Last update posted | Sep 11, 2014 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: